VTUS - VTUS "hold", target reduced to $1.25 (OKAY by me because most-likely I will be gone before then. I will take $1.25)
Wednesday, May 28, 2014 1:55 PM EDT
Cantor Fitzgerald
May 28 (FlashRatings.com) - Analysts at Cantor Fitzgerald maintain their "hold" rating for Ventrus Biosciences, Inc. (VTUS). The target price is reduced from $2.5 to $1.25.
In a research note published this morning, the analysts mention that the company has reported a net loss per share for 1Q14 slightly higher than was expected. Ventrus Biosciences has announced its plans to merge with privately held Assembly Pharmaceuticals in July and issue 20 million shares to finance the all-stock transaction. The analysts express their concern regarding the uncertainties surrounding Ventrus Biosciences’ late-stage diltiazem NDA submission for anal fissure pain, which is the main reason for the lowered target price.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.